TechInvest

TechInvest An online news and information community, showcasing some of Australasia’s most innovative technol
(8)

Battery materials and technology company NOVONIX Limited (ASX: NVX) has announced the signing of a joint development agr...
08/08/2024

Battery materials and technology company NOVONIX Limited (ASX: NVX) has announced the signing of a joint development agreement focused on nickel-based cathode materials with Brazilian headquartered niobium products leader CBMM.

NOVONIX and CBMM enter into Joint Development Agreement

DUG Technology (ASX: DUG) has signed an exclusive DUG Cool licensing agreement with Baltimore Aircoil Company, Inc (BAC)...
08/08/2024

DUG Technology (ASX: DUG) has signed an exclusive DUG Cool licensing agreement with Baltimore Aircoil Company, Inc (BAC).

DUG inks exclusive DUG Cool licensing agreement with BAC

Armis doubles recurring revenue to US$200m in less than 18 months
08/08/2024

Armis doubles recurring revenue to US$200m in less than 18 months

Armis doubles recurring revenue to US$200m in less than 18 months

Nyrada Inc (ASX:NYR) has received additional study data to support the safety and tolerability of its lead brain injury ...
08/08/2024

Nyrada Inc (ASX:NYR) has received additional study data to support the safety and tolerability of its lead brain injury drug candidate.

Nyrada receives positive brain injury programme studies update

Enlitic, Inc. (ASX: ENL) has reached an agreement to sell CXR Focal Opacity, Enlitic’s chest x-ray technology, to Clairv...
07/08/2024

Enlitic, Inc. (ASX: ENL) has reached an agreement to sell CXR Focal Opacity, Enlitic’s chest x-ray technology, to Clairvo Technologies for a cash consideration of US$500,000.

Enlitic sells CXR Focal Opacity to Clairvo

Lumos Diagnostics (ASX: LDX) has received a cash refund of $140,777 related to its Research and Development Tax Incentiv...
07/08/2024

Lumos Diagnostics (ASX: LDX) has received a cash refund of $140,777 related to its Research and Development Tax Incentive for the FY2023 financial year ended 30 June 2023.

Lumos receives Research & Development Tax Rebate

Australian biological company Terragen Holdings (ASX:TGH) has revealed positive results of research conducted by the Dep...
07/08/2024

Australian biological company Terragen Holdings (ASX:TGH) has revealed positive results of research conducted by the Department of Energy, Environment and Climate Action (DEECA) at their Hamilton Smart Farm, Victoria.

Terragen's feed supplement improves weight gain in lambs

Amplia Therapeutics (ASX: ATX) has confirmed that an additional patient in the company’s ACCENT trial in pancreatic canc...
07/08/2024

Amplia Therapeutics (ASX: ATX) has confirmed that an additional patient in the company’s ACCENT trial in pancreatic cancer has recorded a confirmed partial response.

Amplia receives additional patient response in pancreatic cancer trial

Axiom Properties' (ASX:AXI) 100%-owned ListSure has entered into a Development and Integration Agreement with Proptech L...
06/08/2024

Axiom Properties' (ASX:AXI) 100%-owned ListSure has entered into a Development and Integration Agreement with Proptech Labs.

Axiom's ListSure partners with Proptech Labs

Austal (ASX: ASB) has delivered the seventh of 10 Evolved Cape-class Patrol Boats (ECCPB’s) under contract to the Royal ...
06/08/2024

Austal (ASX: ASB) has delivered the seventh of 10 Evolved Cape-class Patrol Boats (ECCPB’s) under contract to the Royal Australian Navy.

Austal delivers 7th Evolved Cape Class Patrol Boat

Australian technology company X2M Connect Limited has signed a Term Sheet with Dicode Technologies LLC to license the ‘V...
06/08/2024

Australian technology company X2M Connect Limited has signed a Term Sheet with Dicode Technologies LLC to license the ‘Vision by X2M’ platform for the Middle East, starting with operations in the United Arab Emirates.

X2M secures Middle East licensing agreement

Iress (ASX: IRE) has completed the sale of its UK Mortgage Sales & Originations business to Bain Capital Tech Opportunit...
06/08/2024

Iress (ASX: IRE) has completed the sale of its UK Mortgage Sales & Originations business to Bain Capital Tech Opportunities LP.

Iress completes sale of its UK Mortgages business

Epsilon Healthcare (ASX: EPN), a leading company in Pharmaceutical Contract Development and Manufacturing & Telehealth o...
06/08/2024

Epsilon Healthcare (ASX: EPN), a leading company in Pharmaceutical Contract Development and Manufacturing & Telehealth operations, has announced the establishment of a new business vertical aimed at enhancing the Company’s strategic growth and diversification efforts.

Epsilon Healthcare announces a new Pharmacy Vertical Integral

learVue Technologies (ASX:CPV) has entered the Middle East and North Africa (MENA) and Indian markets with a Manufacturi...
06/08/2024

learVue Technologies (ASX:CPV) has entered the Middle East and North Africa (MENA) and Indian markets with a Manufacturing and Distribution agreement with Aluminium Technology Auxiliary Industries WLL (Alutec).

ClearVue enters Middle East and Indian construction markets

Advanced memory technologies company Weebit Nano (ASX:WBT) and tier-1 semiconductor foundry DB HiTek have released to ma...
02/08/2024

Advanced memory technologies company Weebit Nano (ASX:WBT) and tier-1 semiconductor foundry DB HiTek have released to manufacturing a demonstration chip.

Weebit and DB HiTek tape-out ReRAM module in BCD process

Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) continues to make progress for its US clinical trials in s...
02/08/2024

Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) continues to make progress for its US clinical trials in support of its FDA application for its ovarian cancer diagnostic blood test.

CLEO selects US clinical trial sites

ReadyTech Holdings (ASX:RDY) has recently advanced its higher education growth strategy with a number of prominent custo...
02/08/2024

ReadyTech Holdings (ASX:RDY) has recently advanced its higher education growth strategy with a number of prominent customer wins.

The total deal value of the above sits at $3.3 million with 50% of revenue to be recognised in FY25.

Iondrive Limited (ASX: ION) has successfully completed its large-scale bench trials including independent verification o...
02/08/2024

Iondrive Limited (ASX: ION) has successfully completed its large-scale bench trials including independent verification of the metal recoveries by Independent Metallurgical Operations (IMO) in Perth.

Large-scale trials validate scalability of Iondrive's technology

Melbourne-headquartered Tryptamine Therapeutics (ASX: TYP) has dosed the first patient in its Phase 2a clinical trial in...
24/07/2024

Melbourne-headquartered Tryptamine Therapeutics (ASX: TYP) has dosed the first patient in its Phase 2a clinical trial investigating the treatment of Irritable Bowel Syndrome (IBS).

Tryptamine doses first patient in new IBS candidate trial at Mass General

LTR Pharma Limited (ASX:LTP) has received firm commitments to raise $10.5 million.
24/07/2024

LTR Pharma Limited (ASX:LTP) has received firm commitments to raise $10.5 million.

LTR Pharma completes A$10.5 million placement

24/07/2024

Australian clean energy company Pure Hydrogen Corporation (ASX:PH2) has signed a Memorandum of Understanding (MOU) with the Vietnam ASEAN Hydrogen Club (VAHC).

Pure Hydrogen signs MOU for multiple buses with the Vietnam ASEAN Hydrogen Club

Clinical stage cell therapy company Chimeric Therapeutics (ASX:CHM) has enrolled the first participant in the Phase 1/2 ...
24/07/2024

Clinical stage cell therapy company Chimeric Therapeutics (ASX:CHM) has enrolled the first participant in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy.

Chimeric enrols first patient in CHM CDH17 Phase 1/2 clinical trial

Clinical-stage biotechnology company Immutep Limited (ASX: IMM) has met with the US Food and Drug Administration (FDA) r...
23/07/2024

Clinical-stage biotechnology company Immutep Limited (ASX: IMM) has met with the US Food and Drug Administration (FDA) regarding the planned TACTI-004 Phase III trial of a treatment of first-line metastatic non-small cell lung cancer.

Immutep holds successful meeting with FDA on Phase III design in NSCLC

23/07/2024

Activeport Group Ltd. (ASX: ATV) has announced the launch of its Network Ecosystem Orchestration (NEO) platform under the Global Edge brand.

Activeport Launches Groundbreaking Network Ecosystem Orchestration Platform for Enterprises

Little Green Pharma Ltd (ASX: LGP) has reported a robust performance in its quarterly activities report and Appendix 4C ...
23/07/2024

Little Green Pharma Ltd (ASX: LGP) has reported a robust performance in its quarterly activities report and Appendix 4C for the quarter ending 30 June 2024.

Little Green Pharma delivers robust quarter

Australian reproductive biotech company Memphasys Limited (ASX: MEM) is prioritising an innovative Oxidative Stress meas...
19/07/2024

Australian reproductive biotech company Memphasys Limited (ASX: MEM) is prioritising an innovative Oxidative Stress measurement system aimed at boosting reproductive performance in animals.

Memphasys Eyes Breakthrough with New Oxidative Stress Measurement for Animal Reproduction

Sydney headquartered medical technology company Next Science Limited (ASX:NXS) has entered into a facility agreement wit...
18/07/2024

Sydney headquartered medical technology company Next Science Limited (ASX:NXS) has entered into a facility agreement with TIGA Trading under which the lender will provide the company with a US$5 million unsecured loan facility.

Next Science enters into US$5m unsecured loan facility

Clinical-stage biotechnology company Immutep (ASX: IMM) has received regulatory clearance from the ethics and competent ...
18/07/2024

Clinical-stage biotechnology company Immutep (ASX: IMM) has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.

Immutep receives regulatory clearance for Phase 1 IMP761 trial

Clinical-stage biotechnology company Immutep ( : $IMM) has received regulatory clearance from the ethics and competent a...
17/07/2024

Clinical-stage biotechnology company Immutep ( : $IMM) has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761.

Immutep receives regulatory clearance for Phase 1 IMP761 trial

Address


Alerts

Be the first to know and let us send you an email when TechInvest posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to TechInvest:

Videos

Shortcuts

  • Address
  • Telephone
  • Alerts
  • Contact The Business
  • Videos
  • Claim ownership or report listing
  • Want your business to be the top-listed Media Company?

Share